Farlow 6-marker panel for Lung Cancer
This study aimed to develop a serum test that could be used to discern NSCLC patients from cancer-free controls and may provide a means to indicate who should have spiral CT done. A large number of potential tumor autoantibodies for NSCLC were identified and validated. The six-analyte blood test that resulted from this study (consisting of IMPDH, phosphoglycerate mutase, ubiquilin, Annexin I, Annexin II, and HSP70-9B) possessed excellent test performance characteristics when tested against our 196 patient cohort that was composed of four clinically distinct groups, with only 13 patients misclassified overall.
There are no datasets associated with this biomarker.